Fig. 7
In vivo antitumor efficacy of FeS2-based NPs in an MNNG-HOS CDX model. (A) Treatment schedule and grouping information on the antitumor study performed on an MNNG-HOS CDX model. (B) Tumor growth curves were recorded on tumor-bearing mice during the treatment trial. (C) Size and (D) weight of isolated tumors from mice in the tested groups at the end time point. (E) The tumor volume growth inhibition rate of mice treated with different NPs. (F) The tumor weight inhibition and (G) the tumor/body weight ratio in each test group at the treatment endpoint. (H) Representative microphotographs of H&E staining, Ki-67-immune-histochemical (Ki-67 IHC) staining, GXP4-immune-histochemical (GXP4 IHC) staining and TUNEL-immunofluorescence (TUNEL-IFC) staining of the tumor sections collected from the treated mice at the endpoint, scale bar = 100 μm. (I) Analysis of the mean density of Ki-67-IHC and GXP4-IHC. (J) Analysis of the apoptosis index of TUNEL-IFC. All data were expressed as the mean ± SD (n = 5, one-way ANOVA with Tukey multi-comparisons. *p < 0.05, **p < 0.01, ***p < 0.001 and ns, no significance)